Davies A, Zoubeidi A, Selth LA. The epigenetic and transcriptional panorama of neuroendocrine prostate most cancers. Endocr Relat Most cancers. 2020;27:R35–50.
Quintanal-Villalonga A, Chan JM, Yu HA, Pe’er D, Sawyers CL, Sen T, et al. Lineage plasticity in most cancers: a shared pathway of therapeutic resistance. Nat Rev Clin Oncol. 2020;17:360–71.
Davies AH, Beltran H, Zoubeidi A. Mobile plasticity and the neuroendocrine phenotype in prostate most cancers. Nat Rev Urol. 2018;15:271–86.
Aparicio A, Logothetis CJ, Maity SN. Understanding the deadly variant of prostate most cancers: energy of analyzing extremes. Most cancers Discov. 2011;1:466–8.
Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, et al. Aggressive variants of castration-resistant prostate most cancers. Clin Most cancers Res. 2014;20:2846–50.
Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, et al. Medical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate most cancers: a multi-institutional potential research. J Clin Oncol. 2018;36:2492–503.
Puca L, Vlachostergios PJ, Beltran H. Neuroendocrine differentiation in prostate most cancers: rising biology, fashions, and therapies. Chilly Spring Harb Perspect Med. 2019;9:a030593.
Kaarijarvi R, Kaljunen H, Ketola Ok. Molecular and purposeful hyperlinks between neurodevelopmental processes and treatment-induced neuroendocrine plasticity in prostate most cancers development. Cancers. 2021;13:692.
Beltran H, Tagawa ST, Park Ok, MacDonald T, Milowsky MI, Mosquera JM, et al. Challenges in recognizing treatment-related neuroendocrine prostate most cancers. J Clin Oncol. 2012;30:e386–9.
Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N. Neuroendocrine differentiation in hormone refractory prostate most cancers following androgen deprivation remedy. Eur Urol. 2004;45:586–92.
Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, et al. Outcomes of a part II research with doxorubicin, etoposide, and cisplatin in sufferers with absolutely characterised small-cell carcinoma of the prostate. J Clin Oncol. 2002;20:3072–80.
Laneve P, Gioia U, Andriotto A, Moretti F, Bozzoni I, Caffarelli E. A minicircuitry involving REST and CREB controls miR-9-2 expression throughout human neuronal differentiation. Nucleic Acids Res. 2010;38:6895–905.
Qureshi IA, Gokhan S, Mehler MF. REST and CoREST are transcriptional and epigenetic regulators of seminal neural destiny choices. Cell Cycle. 2010;9:4477–86.
Wu J, Xie X. Comparative sequence evaluation reveals an intricate community amongst REST, CREB and miRNA in mediating neuronal gene expression. Genome Biol. 2006;7:R85.
Negrini S, Prada I, D’Alessandro R, Meldolesi J. REST: an oncogene or a tumor suppressor? Developments Cell Biol. 2013;23:289–95.
Liang H, Studach L, Hullinger RL, Xie J, Andrisani OM. Down-regulation of RE-1 silencing transcription issue (REST) in superior prostate most cancers by hypoxia-induced miR-106b~25. Exp Cell Res. 2014;320:188–99.
Svensson C, Ceder J, Iglesias-Gato D, Chuan YC, Pang ST, Bjartell A, et al. REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate most cancers. Nucleic Acids Res. 2014;42:999–1015.
Lin TP, Chang YT, Lee SY, Campbell M, Wang TC, Shen SH, et al. REST discount is important for hypoxia-induced neuroendocrine differentiation of prostate most cancers cells by activating autophagy signaling. Oncotarget. 2016;7:26137–51.
Chang YT, Lin TP, Campbell M, Pan CC, Lee SH, Lee HC, et al. REST is a vital regulator for buying EMT-like and stemness phenotypes in hormone-refractory prostate most cancers. Sci Rep. 2017;7:42795.
Zhang Y, Zheng D, Zhou T, Track H, Hulsurkar M, Su N, et al. Androgen deprivation promotes neuroendocrine differentiation and angiogenesis by way of CREB-EZH2-TSP1 pathway in prostate cancers. Nat Commun. 2018;9:4080.
Deng X, Liu H, Huang J, Cheng L, Keller ET, Parsons SJ, et al. Ionizing radiation induces prostate most cancers neuroendocrine differentiation by way of interaction of CREB and ATF2: implications for illness development. Most cancers Res. 2008;68:9663–70.
Suarez CD, Deng X, Hu CD. Focusing on CREB inhibits radiation-induced neuroendocrine differentiation and will increase radiation-induced cell dying in prostate most cancers cells. Am J Most cancers Res. 2014;4:850–61.
Hu CD, Choo R, Huang J. Neuroendocrine differentiation in prostate most cancers: a mechanism of radioresistance and therapy failure. Entrance Oncol. 2015;5:90.
Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, et al. Repression of E-cadherin by the polycomb group protein EZH2 in most cancers. Oncogene. 2008;27:7274–84.
Cha TL, Zhou BP, Xia W, Wu Y, Yang CC, Chen CT, et al. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science. 2005;310:306–10.
Wang L, Jin Q, Lee JE, Su IH, Ge Ok. Histone H3K27 methyltransferase Ezh2 represses Wnt genes to facilitate adipogenesis. Proc Natl Acad Sci USA. 2010;107:7317–22.
Yamaguchi H, Hung MC. Regulation and position of EZH2 in Most cancers. Most cancers Res Deal with. 2014;46:209–22.
Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al. Function of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002;298:1039–43.
Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in most cancers epigenetics. Mutat Res. 2008;647:21–9.
Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, et al. The polycomb group protein EZH2 immediately controls DNA methylation. Nature. 2006;439:871–4.
Crea F, Fornaro L, Bocci G, Solar L, Farrar WL, Falcone A, et al. EZH2 inhibition: concentrating on the crossroad of tumor invasion and angiogenesis. Most cancers Metastasis Rev. 2012;31:753–61.
Friedman JM, Liang G, Liu CC, Wolff EM, Tsai YC, Ye W, et al. The putative tumor suppressor microRNA-101 modulates the most cancers epigenome by repressing the polycomb group protein EZH2. Most cancers Res. 2009;69:2623–9.
Kikuchi J, Takashina T, Kinoshita I, Kikuchi E, Shimizu Y, Sakakibara-Konishi J, et al. Epigenetic remedy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits progress of non-small cell lung most cancers cells. Lung Most cancers. 2012;78:138–43.
Pal B, Bouras T, Shi W, Vaillant F, Sheridan JM, Fu N, et al. International modifications within the mammary epigenome are induced by hormonal cues and coordinated by Ezh2. Cell Rep. 2013;3:411–26.
Shin YJ, Kim JH. The position of EZH2 within the regulation of the exercise of matrix metalloproteinases in prostate most cancers cells. PloS one. 2012;7:e30393.
Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, et al. Genomic lack of microRNA-101 results in overexpression of histone methyltransferase EZH2 in most cancers. Science. 2008;322:1695–9.
Wan L, Li X, Shen H, Bai X. Quantitative evaluation of EZH2 expression and its correlations with lung most cancers sufferers’ scientific pathological traits. Clin Transl Oncol. 2013;15:132–8.
Yang YA, Yu J. EZH2, an epigenetic driver of prostate most cancers. Protein Cell. 2013;4:331–41.
Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate most cancers. Nat. Med. 2016;22:298–305.
Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, et al. Rb1 and Trp53 cooperate to suppress prostate most cancers lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017;355:78–83.
Clermont PL, Lin D, Crea F, Wu R, Xue H, Wang Y, et al. Polycomb-mediated silencing in neuroendocrine prostate most cancers. Clin Epigenetics. 2015;7:40.
Xu Ok, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, et al. EZH2 oncogenic exercise in castration-resistant prostate most cancers cells is Polycomb-independent. Science. 2012;338:1465–9.
Zhao JC, Yu J, Runkle C, Wu L, Hu M, Wu D, et al. Cooperation between Polycomb and androgen receptor throughout oncogenic transformation. Genome Res. 2012;22:322–31.
Beltran H, Rickman DS, Park Ok, Chae SS, Sboner A, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate most cancers and identification of recent drug targets. Most cancers Discov. 2011;1:487–95.
Rockowitz S, Lien WH, Pedrosa E, Wei G, Lin M, Zhao Ok, et al. Comparability of REST cistromes throughout human cell sorts reveals widespread and context-specific features. PLoS Comput Biol. 2014;10:e1003671.
Erkek S, Johann PD, Finetti MA, Drosos Y, Chou HC, Zapatka M, et al. Complete evaluation of chromatin states in atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and polycomb in gene regulation. Most cancers Cell. 2019;35:95–110.e8.
Qadeer ZA, Valle-Garcia D, Hasson D, Solar Z, Prepare dinner A, Nguyen C, et al. ATRX in-frame fusion neuroblastoma is delicate to EZH2 inhibition by way of modulation of neuronal gene signatures. Most cancers Cell. 2019;36:512–527.e9.
Dietrich N, Lerdrup M, Landt E, Agrawal-Singh S, Bak M, Tommerup N, et al. REST-mediated recruitment of polycomb repressor complexes in mammalian cells. PLoS Genet. 2012;8:e1002494.
Mozzetta C, Pontis J, Fritsch L, Robin P, Portoso M, Proux C, et al. The histone H3 lysine 9 methyltransferases G9a and GLP regulate polycomb repressive advanced 2-mediated gene silencing. Mol Cell. 2014;53:277–89.
Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, et al. Lengthy noncoding RNA as modular scaffold of histone modification complexes. Science. 2010;329:689–93.
Lee SW, Oh YM, Lu YL, Kim WK, Yoo AS. MicroRNAs overcome cell destiny barrier by lowering EZH2-Managed REST Stability throughout neuronal conversion of human grownup fibroblasts. Dev Cell. 2018;46:73–84.e7.
Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of scientific consequence in superior prostate most cancers. Proc Natl Acad Sci USA. 2019;116:11428–36.
Tai S, Solar Y, Squires JM, Zhang H, Oh WK, Liang CZ, et al. PC3 is a cell line attribute of prostatic small cell carcinoma. Prostate. 2011;71:1668–79.
Chen WY, Zeng T, Wen YC, Yeh HL, Jiang KC, Chen WH, et al. Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate most cancers. Most cancers Lett. 2019;440-441:35–46.
Dang Q, Li L, Xie H, He D, Chen J, Track W, et al. Anti-androgen enzalutamide enhances prostate most cancers neuroendocrine (NE) differentiation by way of altering the infiltrated mast cells -> androgen receptor (AR) -> miRNA32 indicators. Mol Oncol. 2015;9:1241–51.
Niu Y, Guo C, Wen S, Tian J, Luo J, Wang Ok, et al. ADT with antiandrogens in prostate most cancers induces adversarial impact of accelerating resistance, neuroendocrine differentiation and tumor metastasis. Most cancers Lett. 2018;439:47–55.
Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate most cancers cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Most cancers. 2007;14:531–47.
Sang M, Hulsurkar M, Zhang X, Track H, Zheng D, Zhang Y, et al. GRK3 is a direct goal of CREB activation and regulates neuroendocrine differentiation of prostate most cancers cells. Oncotarget. 2016;7:45171–85.
de Graaf C, Rognan D. Selective structure-based digital screening for full and partial agonists of the beta2 adrenergic receptor. J Med Chem. 2008;51:4978–85.
Dishy V, Sofowora GG, Xie HG, Kim RB, Byrne DW, Stein CM, et al. The impact of widespread polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N. Engl J Med. 2001;345:1030–5.
Heisler S, Reisine T. Forskolin stimulates adenylate cyclase exercise, cyclic AMP accumulation, and adrenocorticotropin secretion from mouse anterior pituitary tumor cells. J Neurochem. 1984;42:1659–66.
Du Ok, Asahara H, Jhala US, Wagner BL, Montminy M. Characterization of a CREB gain-of-function mutant with constitutive transcriptional exercise in vivo. Mol Cell Biol. 2000;20:4320–7.
Hulsurkar M, Li Z, Zhang Y, Li X, Zheng D, Li W. Beta-adrenergic signaling promotes tumor angiogenesis and prostate most cancers development by way of HDAC2-mediated suppression of thrombospondin-1. Oncogene. 2017;36:1525–36.
Li Y, Donmez N, Sahinalp C, Xie N, Wang Y, Xue H, et al. SRRM4 Drives neuroendocrine transdifferentiation of prostate adenocarcinoma below androgen receptor pathway inhibition. Eur Urol. 2017;71:68–78.
Wagoner MP, Gunsalus KT, Schoenike B, Richardson AL, Friedl A, Roopra A. The transcription issue REST is misplaced in aggressive breast most cancers. PLoS Genet. 2010;6:e1000979.
Westbrook TF, Hu G, Ang XL, Mulligan P, Pavlova NN, Liang A, et al. SCFbeta-TRCP controls oncogenic transformation and neural differentiation by way of REST degradation. Nature. 2008;452:370–4.
Zhang X, Coleman IM, Brown LG, True LD, Kollath L, Lucas JM, et al. SRRM4 expression and the lack of REST exercise might promote the emergence of the neuroendocrine phenotype in castration-resistant prostate most cancers. Clin Most cancers Res. 2015;21:4698–708.
Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate most cancers. Science. 2017;355:84–8.
Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ, et al. Number of extremely metastatic variants of various human prostatic carcinomas utilizing orthotopic implantation in nude mice. Medical most cancers analysis : an official journal of the American Affiliation for. Most cancers Res. 1996;2:1627–36.
Yuan TC, Veeramani S, Lin FF, Kondrikou D, Zelivianski S, Igawa T, et al. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr Relat Most cancers. 2006;13:151–67.
Kleb B, Estecio MR, Zhang J, Tzelepi V, Chung W, Jelinek J, et al. Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas. Epigenetics. 2016;11:184–93.
Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G, et al. A lentiviral RNAi library for human and mouse genes utilized to an arrayed viral high-content display screen. Cell. 2006;124:1283–98.
Kim KH, Kim W, Howard TP, Vazquez F, Tsherniak A, Wu JN, et al. SWI/SNF-mutant cancers rely upon catalytic and non-catalytic exercise of EZH2. Nat Med. 2015;21:1491–6.
Pearlberg J, Degot S, Endege W, Park J, Davies J, Gelfand E, et al. Screens utilizing RNAi and cDNA expression as surrogates for genetics in mammalian tissue tradition cells. Chilly Spring Harb Symp Quant Biol. 2005;70:449–59.
Li W, Ai N, Wang S, Bhattacharya N, Vrbanac V, Collins M, et al. GRK3 is important for metastatic cells and promotes prostate tumor development. Proc Natl Acad Sci USA. 2014;111:1521–6.
Li L, Su N, Zhou T, Zheng D, Wang Z, Chen H, et al. Blended lineage kinase ZAK promotes epithelial-mesenchymal transition in most cancers development. Cell Dying Dis. 2018;9:143.
Wang Z, Hulsurkar M, Zhuo L, Xu J, Yang H, Naderinezhad S, et al. CKB inhibits epithelial-mesenchymal transition and prostate most cancers development by sequestering and inhibiting AKT activation. Neoplasia. 2021;23:1147–65.
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio most cancers genomics portal: an open platform for exploring multidimensional most cancers genomics knowledge. Most cancers Discov. 2012;2:401–4.
